









































One of the most intriguing questions in stem cell 
biology is whether pluripotent stem cells (PSCs) exist in 
adult tissues. Several groups of investigators employing 
i) various isolation protocols, ii) detection of surface 
markers, and iii) experimental in vitro and in vivo 
models, have reported the presence of cells that possess 
a pluripotent character in adult tissues [1-4].  Such cells 
were assigned various operational abbreviations and 
names in the literature that added confusion to the field 
and raised the basic question of whether  these  are  truly  
 
 









































distinct or overlapping populations of the same 
primitive stem cells. Unfortunately, these cells were 
never characterized side-by-side to address this 
important issue. Nevertheless, taking into consideration 
their common features described in the literature, it is 
very likely that various investigators have described 
overlapping populations of developmentally early stem 
cells that are closely related [1-6].   
 
From a developmental point of view, another important 
question is why should PSCs reside in adult organs? For 
many years it has been accepted that adult tissues 





























our and other  laboratories demonstrated  that both murine and human VSELs exhibit  some  characteristics of  long‐term
repopulating hematopoietic  stem  cells  (LT‐HSCs), are at  the  top of  the hierarchy  in  the mesenchymal  lineage, and may
differentiate into organ‐specific cells (e.g., cardiomyocytes). Moreover, as recently demonstrated the number of these cells
positively  correlates  in  several  murine  models  with  longevity.  Finally,  while  murine  BM‐derived  VSELs  have  been
extensively characterized more work is needed to better characterize these small cells at the molecular level in humans.     
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contain only tissue-committed stem cells (TCSCs), such 
as epidermal stem cells, hematopoietic stem cells, or 
skeletal muscle stem cells, that have a limited potential 
for differentiation [7-11].  To address this question, we 
consider two scenarios that could occur during early 
embryogenesis and the development of lineage-
restricted TCSCs [1,12,13]. In the first scenario, PSCs 
present in the inner cell mass of the blastocyst/epiblast, 
after giving rise to more differentiated lineage-restricted 
TCSCs, gradually disappear from the growing embryo 
and do not reside in adult tissues. In the second 
scenario, which we believe is more likely to take place 
during embryogenesis, some PSCs give rise to TCSCs 
but some survive in adult tissues as a backup population 
of PSCs that renews the pool of TCSCs over time. In 
this scenario, PSCs are precursors of TCSCs during 
organ/tissue rejuvenation and a source of these cells in 
emergency situations when organs are damaged (e.g., 
heart infarct or stroke). This scenario, however, requires 
such PSCs population deposited in adult tissues to be 
kept under control and in a quiescent state, which is 
essential to preventing uncontrolled proliferation 
leading to teratoma formation. 
 
In this review, we will discuss the second scenario, in 
which population of very small embryonic- like stem 
cells (VSELs) - a rare population of epiblast-derived 
PSCs deposited in adult tissues is a reserve pool for 
TCSCs [1,14,15]. We will also present the most recent 
observations from our and other laboratories that 
support the presence of developmentally primitive stem 
cells in adult tissues with broad potential to differentiate 
into multiple lineages, which correspond to the VSELs 
described by our team.       
 
Data supporting the presence of small stem cells in 
adult tissues 
 
As mentioned above, several primitive cells with the 
characteristics of pluripotent or multipotent stem cells 
were isolated from adult murine and human tissues after 
expansion in in vitro cultures of cell suspensions 
isolated from murine and human bone marrow (BM) or 
human umbilical cord blood (UCB) or derived from 
adult organs after enzymatic processing by proteolytic 
enzymes [3-5,16,17]. In these in vitro cultures, in which 
cells grow while adhering to plastic or fibronectin, 
several populations of primitive cells were isolated, 
expanded and assigned different operational names 
[2,3,5,6,17-20]. Unfortunately, in none of these 
isolation procedures the phenotype of stem cell that 
initiated these cultures has been described clear from 
the beginning and the expanded in vitro cells were 
variously described as multipotent adult stem cells 
(MASCs) (19), unrestricted somatic stem cells (USSCs) 
[4,21,22] or marrow-isolated adult multilineage-
inducible (MIAMI) cells [2].  
 
In parallel, other isolation strategies were also 
employed, and an interesting population of small cells 
(ELH stem cells) able to differentiate into epithelial 
cells and hematopoietic cells was isolated from the 
murine BM by elutriation (E), lineage depletion (L), and 
the ability to home (H) to BM [23-25]. On the other 
hand, small cells able to differentiate into cells from all 
germ layers and called "spore-like stem cells" were 
isolated from adult mammalian tissues; however, the 
strategy by which they were purified and which surface 
markers they express was not provided in the original 
report [26].  
 
Nevertheless, the presence of these primarily non-
hematopoietic stem cells residing in adult BM 
challenged the concept of stem cell plasticity, which 
was supported by some data suggesting that 
hematopoietic stem cells (HSCs) may trans-differentiate 
into cells for non-hematopoietic tissues in murine 
models of experimental heart infarct, stroke, or liver 
damage [27,28]. The data in some of the experiments 
that showed a contribution of grafted BM cells into non-
hematopoietic lineages gave the false impression that 
hematopoietic stem cells (HSCs) had trans-
differentiated into cells for non-hematopoietic tissues 
[29, 30].  
 
Rejecting the concept that trans-differentiation of adult 
HSCs into non-hematopoietic lineages is a frequent 
biological phenomenon, our main aim became to isolate 
a population of true PSCs from BM, which could 
explain the data showing a contribution from BM cells 
in the regeneration of damaged organs. Based on 
preliminary data gained from our initial experiments, 
we purified from adult murine BM a population of cells 
slightly smaller than red blood cells that expressed the 
surface phenotype Sca1+Lin–CD45– and markers of 
pluripotent stem cells (e.g., Oct4, Nanog, and SSEA-4). 
These cells displayed a distinct morphology 
characterized by a high nuclear/cytoplasmic ratio and 
undifferentiated chromatin [31, 32].  Phenotypically 
similar cells were subsequently purified from murine 
fetal liver, as well as from several adult murine organs, 
including brain, skeletal muscle, kidney, lung, liver, and 
pancreas [33-36].   
 
Small cells comprising population of human VSELs 
were also purified from neonatal umbilical cord blood 
(UCB) and adult patient-mobilized peripheral blood 
(mPB) [37-43]. Human UCB and mPB are enriched in 
VSELs within a population of CD133+Lin–CD45– cells 
that co-express CXCR4, and some of them are also 
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CD34+. Like their murine counterparts, human UCB 
and mPB VSELs also express Oct4 and Nanog 
transcription factors in nuclei and express SSEA-1 on 
the surface [37-42]. The procedure for how to purify 
these cells has been described in detail in several 
publications and summarized in Current Protocols in 
Cytometry [44] and Methods in Cell Biology [14]. In 
this review, we will focus on new observations 
generated by our team, as well as the work of other 
groups working on VSELs or closely related cells. 
 
Reports by other groups on cells that are 
attributable to VSELs and closely related cells 
 
The most common feature of VSELs is that they 
possess very primitive morphology and relatively small 
size [31,32,37,39]. Recently, there have been several 
published reports that support the existence of small, 
primitive VSELs or VSEL-like cells in adult tissues, 
and we will briefly discuss the most important of these 
observations [45-51].   
 
In one report, a population of murine VSELs was 
isolated from BM, and in a set of elegant experiments, 
these cells were demonstrated to be able to give rise to 
mesenchymal and endothelial lineages [49]. The bone-
forming activity of these cells, if embedded in gelatin 
sponges and implanted into living mice, exceeded the 
activity of other populations of BM-purified cells tested 
in the same assay. Based on this finding, it has been 
proposed that Sca-1+Lin–CD45– VSELs are at the top of 
the hierarchy for the mesenchymal and endothelial 
lineages in BM [49].   
 
In another report, VSELs were purified from rat BM 
and successfully employed to regenerate damaged 
myocardium in an experimental rodent model of acute 
myocardial infarction [52]. These cells expressed 
SSEA-1 antigen on their surface and Oct-4 in their 
nuclei. Similarly, small non-hematopoietic murine 
BM-derived cells that correspond in size to VSELs 
were also shown to give rise to type 2 pneumocytes, 
which produce lung surfactant protein after 
transplantation into surfactant-deficient mice [46]. In 
order to determine whether surfactant-producing 
epithelial cells were derived from the non-
hematopoietic or the hemato-poietic fraction of BM 
cells that were used to treat surfactant-deficient mice, 
the authors employed a lineage-tracing approach in 
which Cre recombinase-specific vav-promoter-
activated green fluorescence protein (GFP) from a 
ROSA–GFP was used as a reporter transgene [46]. 
Small cells with VSEL markers were also identified in 
murine neonatal retina [36], and in another report it 
was demonstrated that small non-hematopoietic 
lineage-negative (lin–) cells isolated from adult BM by 
elutriation (Fraction 25 or Fr25) were involved in 
retinal regeneration following the induction of anterior 
ischemic optic neuropathy and optic nerve crush in a 
rodent model [53]. Similar population of non-
hematopoietic CD45-negative small stem cells 
harvested from BM via elutriation, has been recently 
shown to give rise into functional insulin-producing 
cells in vivo in chemically induced diabetic mice [45]. 
Finally, several features of VSELs are displayed in so-
called multilineage-differentiating, stress-enduring 
(Muse) cells recently isolated from murine and human 
BM populations [48, 54]. These cells may play a major 
role as populations of cells that preferentially give rise 
to induced pluripotent stem cells (iPSCs) when BM-
derived stromal cells are induced to pluripotency by 
genetic manipulation [48,54].  
 
The presence of VSELs in human tissues has also been 
supported by several recent publications. In particular, 
UCB-VSELs have been successfully purified by another 
team [55], and cells corresponding to VSELs were 
purified from UCB by other investigators and described 
as a population of UCB-derived embryonic-like stem 
cells [17,56,57]. A corresponding population of 
primitive stem cells that resembles VSELs named as 
Omnicytes was also described as circulating in UCB 
and being capable to migrate into maternal circulatory 
system [58,59]. Finally, cells similar to UCB-VSELs 
were reported to reside in an ovarian epithelial layer in 
postmenopausal ovaries [47].  
 
Thus, mounting evidence supports the conclusion that 
small cells described as VSELs or VSEL-like cells that 
express developmentally primitive markers reside in 
adult murine and human tissues. However, to confirm 
that these populations of small primitive stem cells, 
such as “Muse” stem cells [48, 54], small non-
hematopoietic Fr25/Lin– BM-derived stem cells [53], 
or ELH stem cells [23, 24], overlap with VSELs 
requires further direct comparison. The detailed 
protocols on how to purify VSELs are published and 
we would be happy to share with other groups our 
expertise in how to isolate these rare cells. Most 
importantly, VSELs are currently purified in several 
laboratories worldwide and the coming years will 
bring more information on their biology and in vitro 
and in vivo differentiation potential.  
 
Recent observations from our group on murine and 
human cells that are attributable to VSELs 
 
In the last years we have put considerable effort into 
better characterizing these rare cells at the molecular 
level.  
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- Progress on VSEL isolation strategies 
VSELs from human UCB and mPB were initially 
purified from an erythrocyte-depleted population of 
nucleated cells by multiparameter sorting as a 
population of small CD133+ CD45– Lin– cells [37]. 
However, this procedure is time consuming and the 
sorting time required to process an entire cord blood 
unit (~50–100 ml) to isolate rare VSELs from UCB 
mononucleated cells takes up to 3–4 days [37]. 
Therefore, from the beginning it has been clear that a 
more rapid and less-expensive method for isolation of 
these cells must be found. In order to establish a more 
efficient method for VSEL purification from UCB, we 
employed a three-step isolation strategy based on 
removal of erythrocytes by hypotonic lysis (1st step), 
followed by immunomagnetic separation of CD133+ 
cells (2nd step), followed by FACS-based isolation of 
CD133+Lin–CD45– cells (3rd step). The entire isolation 
procedure takes only 2–4 hours per 100 ml of UCB 
[39,44].  
 
As an alternative strategy, we recently proposed to 
reduce the number of lineage factors required for 
purification by exposure of erythrocyte-depleted, 
immunomagnetic bead-selected CD133+ cells to 
Aldefluor, followed by staining with anti-CD133+ 
antibodies and only two lineage-specific antibodies 
(anti-CD45 and anti-GlyA) for step 3 [38]. Aldefluor is 
a substrate for aldehyde-dehydrogenase (ALDH), a 
cytosolic enzyme highly expressed in less-differentiated 
hematopoietic cells, and is implicated in resistance to 
some alkylating agents [60,61]. In the presence of 
ALDH, Aldefluor becomes modified to a fluorescent 
molecule that may then be used to mark ALDH-
expressing cells. Inclusion of anti-GlyA antibody is 
based on the well-known fact that small erythroblast 
GlyA+ cells present in UCB do not express the CD45 
antigen. Thus, selection for CD45– cells could enrich for 
these unwanted cells. By employing this strategy, we 
are able to subsequently sort CD133+ cells enriched for 
VSELs and are able to obtain ~103 CD133+/ CD45–
/GlyA–/ALDHlow and 4x103 CD133+/ CD45–/GlyA–
/ALDHhigh UCB-VSELs from 100 ml of UCB [38]. 
These numbers demonstrate how rare these cells are in 
UCB. When we compared both fractions of VSELs by 
RT-PCR gene expression analysis, we found that 
CD133+/CD45–/GlyA–/ALDHlow VSELs have a higher 
expression of Oct4 than the CD133+/CD45–/GlyA–
/ALDHhigh fraction [38]. 
 
However, we are aware that there is yet room to 
improve sorting and to develop alternative strategies for 
purifying UCB-VSELs. To accomplish this goal, one 
should consider the use of metabolic fluorochromes to 
see whether VSELs are enriched among Rh123dull, 
Pyronin Ylow, and Hoechst 33342low cells. Moreover, we 
expect that our proteomics data analysis with UCB-
VSELs will reveal the presence of new positive markers 
that could be employed for purification of these rare 
cells. 
 
- Mobilization of VSELs into PB in response to 
organ/tissue damage 
VSELs circulate in PB under steady-state conditions; 
however, the number of these cells is very low. In our 
recent work we provided evidence that VSELs can be 
mobilized into peripheral blood in adult patients 
injected with granulocyte-colony stimulating factor (G-
CSF). This observation laid the foundation for the 
concept that G-CSF mobilization can be employed to 
harvest these cells from patients for therapeutic 
purposes.   
 
Furthermore, our studies on VSEL mobilization into PB 
revealed that VSELs are mobilized not only, as 
described previously, in patients suffering from heart 
infarct [40,42,62] or stroke [41] but also in patients 
suffering from skin burns [63], active inflammatory 
bowel disease [64], and cancer [14]. More importantly, 
based on our preliminary data, we also envision that the 
number of VSELs circulating in PB in patients could be 
of prognostic value. This however, requires further 
study and long-term clinical correlations. 
 
- Novel characteristics of human VSELs 
In the past two years we investigated several 
experimental approaches to better characterizing murine 
and human UCB-derived VSELs, both at the molecular 
and morphological levels. First, our molecular gene 
array analysis studies on limited numbers of highly 
purified VSELs revealed that murine VSELs are 
somewhat heterogenous developmentally [65-68]. In 
particular, while all of them express the pluripotency 
marker Oct-4, some of them express genes that are more 
closely related to genes expressed by epiblast-derived 
stem cells and others to genes expressed by migrating 
primordial germ cells. This shows that VSELs resemble 
early stem cells developmentally; if isolated from adult 
BM, they may differ somewhat in their differentiation 
potential [65-68].  
 
Based on well-established FACS identification 
protocols, we also found that CD133+Lin–CD45– 
VSELs identified in UCB (Figure 1 panel A), like their 
murine counterparts, i) highly express telomerase (not 
published), ii) are diploid (Figure 1 panel B), and iii) are 
viable, as shown by their ability to exclude the viability 
dye (7-aminoactinomycin D [7-AAD], Figure 1 panel 
C). Importantly, we observed that the highest number of 
pluripotent Oct-4+ VSELs reside in the population of 
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CD133+Lin–CD45– UCB-derived cells [37,39]. 
Moreover, some of the CD133+Lin–CD45– VSELs, 
which represent only a very small subfraction among 
UCB Lin–CD45– non-hematopoietic cells, may co-
express other stem cell markers, including CD34, 
CXCR4, and SSEA-4 [37,39]. Thus, VSELs represent a 
very rare subpopulation of UCB stem cells among Lin–
CD45– non-hematopoietic UCB cells, which contains 
other stem cell types, including endothelial progenitor 
cells (EPCs) and mesenchymal stem cells (MSCs), and 
may be identified based on very small size 
(FSClow/SSClow) and co-expression of CD133, CD34, 









































- In vitro and in vivo evidence that VSELs could be 
pluripotent stem cells 
There are stringent criteria for classifying a stem cell as 
a PSC. In Table I are listed the most important in vitro 
and in vivo criteria that we expect from PSCs. These 
criteria were established by embryologists who are 
working with embryonic stem cells (ESCs) isolated 
from embryos or on established in vitro-immortalized 
ESC lines or induced pluripotent stem cells (iPSCs). 
However, some of these stringent criteria listed as in 
vivo criteria of pluripotency, such as complementation 
of blastocyst development and teratoma formation 
(Table I), are not always visible in pluripotent epiblast-











































A shows a well‐established  flow cytometric protocol  for  identification of CD133+Lin–CD45– VSELs among
the  whole‐nucleated  fraction  of  UCB  cells.  The  dot‐plot  (left)  visualizes  cells  based  on  FSC  and  SSC
parameters,  indicating  the  relative  cellular  size  and  complexity,  respectively.  The  FSClow/SSClow
lymphocytic population, which  includes very  small objects,  is enclosed  in  region P1, and  the cells were
further analyzed according to hematopoietic lineage marker expression (middle histogram). Lin– cells from
region P2 are plotted in the dot‐plot representing CD133 and CD45 expression (right). VSELs are identified
as  CD133+Lin–CD45–  cells  (region Q4), while HSCs  are  identified  as  CD133+Lin–CD45+  cells  (region Q2).
Percentages  indicate  the  content  of  both  stem  cell  populations  among  all  nucleated  cells  in  one
representative UCB  sample. Panel B presents a  representative analysis of DNA  content  in UCB‐derived
VSELs  and  HSCs  following  fixation  and  staining  with  propidium  iodide  (PI).  The  percentages  indicate
normal  diploid  (2n)  VSEL  and  HSC  fractions  in  the G0/G1  phase  of  the  cell  cycle.  Panel  C  shows  the
viability of VSELs and HSCs examined by flow cytometry following the staining of freshly isolated cells with
a viability dye, 7‐aminoactinomycin D  (7‐AAD). Viable VSELs and HSCs are  represented as 7‐AAD–  cells,
which exclude the dye, and their percentage content is computed for each of the stem cell populations.   
  





























Our most recent experimental data support the 
conclusion that murine VSELs fulfill all the in vitro 
criteria listed in Table I. In particular, murine VSELs 
not only possess the primitive morphology of early 
developmental cells but also express typical markers for 
PSCs (e.g., Oct-4, Nanog, and Rex-1) [31,33,34,37,71]. 
Significantly, we also recently confirmed the true 
expression of Oct-4 in murine VSELs (which was 
previously supported by the presence of an open-type 
chromatin in the Oct-4 promoter) by direct analysis of 
its methylation state [72] and association with 
transcription-permissive histones [65,66]. Specifically, 
we observed that the Oct-4 promoter in murine VSELs 
is hypomethylated, and by employing the carrier-ChIP 
assay, we found that the chromatin in the Oct-4 
promoter is associated with the gene transcription-
promoting histone H3Ac, while its association with the 
transcription-restricting histone H3K9me2 is relatively 
low [65,66,72]. We also evaluated the epigenetic state of 
another core transcription factor, Nanog, and observed 
that its promoter has a higher level of methylation in 
VSELs (~50%). In quantitative ChIP experiments 
performed in parallel, we also observed that the 
H3Ac/H3K9me2 ratio favors transcription and supports 
an active state [65,66,72]. Based on these results, we 






























embryonic transcription factors Oct-4 and Nanog. 
 
With respect to the other in vitro criteria of pluripotency 
(Table I), murine VSELs also possess bivalent domains 
in promoters that encode developmentally important 
homeobox-containing transcription factors (Sox21, 
Nkx2.2, Dlx1, Lbx1h, Hlxb9, Pax5, and HoxA3) [68]. 
Furthermore, VSELs derived from female mice 
reactivate the X-chromosome.  
 
Finally, we succeeded in differentiation of VSELs in 
vitro into cells from all three germ layers, while recently 
published data demonstrated that murine BM-derived 
VSELs can be specified in vivo into HSCs (73), 
mesenchymal stem cells (MSCs) [49], and 
cardiomyocytes [74,75].  
 
Our in vitro data on differentiation of human VSELs are 
limited at this point but so far we have shown that 
human UCB-derived VSELs, under appropriate culture 
conditions, can also be specified into the hematopoietic 
lineage [38].   
 
However, taking into consideration the in vivo criteria 
expected from PSCs (Table I), murine VSELs do not 
complete blastocyst development and do not  grow  tera- 
Table I. In vitro and in vivo features of pluripotent stem cells (PSCs)
In vitro criteria for PSCs VSELs 
1. Undifferentiated morphology, euchromatin, and high 
nuclear/cytoplasm ratio 
2.   PSC markers (e.g., Oct-4, Nanog, and SSEA), open chromatin 
at the Oct-4 promoter, bivalent domains, and female PSCs 
reactivate the X chromosome  
3.    Multilineage differentiation into cells from all three germ   







In vivo criteria for PSCs VSELs 
1. Complementation of blastocyst development  
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tomas. This discrepancy between in vitro and in vivo 
criteria of PSCs for VSELs has recently been explained 
by epigenetic changes in expression of some paternally 
imprinted genes [67,72]. This phenomenon will be 
discussed below in the context of the developmental 
origin of VSELs and the mechanisms that keep them 
quiescent in adult tissues and prevent them from 
uncontrolled proliferation and teratoma formation 
[67,72]. 
 
Novel molecular evidence supporting the 
developmental origin of VSELs 
 
As mentioned above, gene expression studies have 
revealed that VSELs express several epiblast and germ 
line markers and we hypothesize that VSELs originate 
from early epiblast-derived migrating primordial germ 
cell (PGC)-like cells, are deposited during development 
in adult tissues as a source of TCSCs, and play a role in 
organ rejuvenation [76,77]. In  support of this notion, 
molecular analysis of murine BM-derived VSELs has 
revealed that these cells express several genes that are 
characteristic of epiblast SCs (Gbx2, Fgf5, and Nodal) 
and germ line specification (Stella, Prdm14, Fragilis, 
Blimp1, Nanos3, and Dnd1) [65,66,72].  
 
However, a main goal of the molecular analysis studies 
was to explain why VSELs do not fulfill the in vivo 
gold-standard criteria expected for PSCs 
(complementation of blastocyst development and 
teratoma formation in immunodeficient animals), which 
are seen with ESCs and iPSCs. To explain this 
discrepancy, we observed that VSELs, in a similar 
manner as late migratory primordial germ cells (PGCs), 
modify the methylation of imprinted genes, preventing 
them from uncontrolled proliferation and explaining 
their quiescent state in adult tissues [65,66].   
 
It is well known that imprinted genes play a crucial role 
in embryogenesis, fetal growth, the totipotential state of 
the zygote, and the pluripotency of developmentally 
early stem cells [78,79]. It has been demonstrated that 
VSELs freshly isolated from murine BM erase the 
paternally methylated imprints at regulatory 
differentially methylated regions (DMRs) within the 
Igf2-H19 and Rasgrf1 loci; however, they also  
hypermethylate the maternally methylated imprints at 
DMRs for the Igf2 receptor (Igf2R), Kcnq1-p57KIP2, and 
Peg1 loci [72]. Because paternally expressed imprinted 
genes (Igf2 and Rasgrf1) enhance embryonic growth 
and maternally expressed genes (H19, p57KIP2, and 
Igf2R) inhibit cell proliferation [72], the unique 
genomic imprinting pattern observed in VSELs 
demonstrates the growth-repressive influence of 
imprinted genes on these cells [72].  
All these results suggest that epigenetic reprogramming 
of genomic imprinting maintains the quiescence of 
Oct4+ epiblast/germ line-derived VSELs deposited in 
the adult body and protects them from premature ageing 
and uncontrolled proliferation (e.g., teratoma 
formation). On the other hand, reversal of this 
mechanism will be crucial to employing VSELs as a 
population of PSCs in regenerative medicine. Currently, 
we are testing whether downregulation of the 
expression of H19 enhances VSEL expansion, as has 
recently been demonstrated for PSCs derived by 
parthenogenesis [80,81]. 
 
The role of murine VSELs in tissue rejuvenation and 
longevity 
 
Interestingly, our most recent work has revealed that 
murine VSELs modulate by epigenetic changes the 
expression of imprinted genes, such as Igf2-H19, 
RasGRF1, and IGF2R, that play an important a role in 
insulin/insulin-like growth factors signaling (IIS), as 
well as a  crucial role in maintaining the pool of VSELs 
residing in adult tissues [82,83]. Accordingly, we 
observed that murine BM-sorted VSELs erase the 
paternally methylated imprints within the DMRs for 
Igf2-H19 and RasGrf1, while they hypermethylate the 
maternally methylated DMR for Igf2R. The epigenetic 
modification of imprinted loci (including Igf2-H19, 
RasGRF1, and IgfR) prevents VSELs from uncontrolled 
proliferation and teratoma formation. This epigenetic 
modification of imprinted genes explains why murine 
VSELs, despite expressing several markers of 
pluripotency (e.g., an open chromatin structure at the 
promoters for Oct-4 and Nanog), the presence of 
bivalent domains at developmentally important 
homeobox-domain containing genes, the reactivation of 
the X chromosome in female VSELs, and in vitro 
differentiation into cells from all three germ layers, do 
not complement blastocyst development after injection 
into the pre-implantation blastocyst (Table I).  
 
To summarize, the abovementioned changes in 
expression of imprinted genes in murine VSELs lead to 
perturbation of IIS by downregulation of  i) IGF2, 
which is an autocrine factor involved in proliferation of 
VSELs, and ii) RasGRF1, which is a GTP-exchange 
factor (GEF) crucial for signaling from activated IGF-
IR and the insulin receptor (InsR, Figure 2). In addition, 
hyperemethylation of DMRs on the maternal 
chromosome encoding IGF-2R [83] has an additional 
negative affect on IIS in VSELs. As mentioned above, 
IGF2R serves as a decoy receptor that prevents IGF-2 
from binding to IGF-IR [83]. This epigenetic 
reprogramming of genomic imprinting negatively 
affects IIS signaling, maintains the quiescent state of 
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murine VSELs, and thus protects them from premature 
depletion from the tissues and prevents their 
involvement in tumor formation.  
 
Based on these findings and published reports that 
elevated IIS signaling negatively affects life span in 
experimental animals [84], we proposed a hypothesis 
that relates aging, longevity, and IIS to the abundance 
and function of pluripotent VSELs deposited in adult 
murine tissues [82,83]. We postulate that a decrease in 
the number of these cells due to prolonged IIS 
negatively affects the pools of TCSCs in various organs 
and has an impact on tissue rejuvenation and life span 
[82,83]. In support of this notion, we observed a 
significantly higher number of VSELs in long-living 
murine strains (e.g., Laron dwarfs and Ames dwarfs), 
whose longevity is explained by low levels of 
circulating IGF1 and a decrease in IIS [85]. By contrast, 



































levels of circulating IGF1 and enhanced IIS (e.g., 
growth hormone-overexpressing transgenic mice) 
compared to normally aging littermates [85]. 
 
The influence of IIS on the pool of VSELs residing in 
adult tissues seems to be twofold (Figure 2). First, since 
IGF2 is an autocrine factor for these cells, 
downregulation of expression of Igf2 and RasGrf1 
together with upregulation of Igf2R, which is a decoy 
receptor for IGF2, keeps VSELs quiescent. At the same 
time, these cells also have high expression of H19 and 
p57Kip2, which are also regulated by imprinting, and 
negatively affect cell proliferation. However, with 
increasing age, the methylation pattern of DMRs at 
paternally imprinted genes in VSELs reverses and Igf2-
H19, as well as RasGrf1, loci become gradually 
methylated, and thus VSELs become more sensitive to 
IIS [83], which may contribute to their age-related 







































would  otherwise  lead  to  their  premature  depletion  from  adult  tissues,  as well  as  trigger  uncontrolled  proliferation  and  teratoma
formation. Left panel – VSELs are protected from autocrine IIS by changes  in expression of  imprinted genes that are  important  in IIS.
Downregulation  of  autocrine  expression  of  IGF2,  upregulation  of  IGF2R  (a  non‐signaling  receptor  that  binds  IGF2  and  prevents  its





with high circulating  IGF1 and  insulin  levels  (e.g., Laron dwarf mice, Ames dwarf mice, or chronic high caloric uptake).   At  the same
time,  chronic  exposure  to  IIS may  also  trigger uncontrolled  activation of VSELs  and  their malignant  transformation.  For  reasons of
simplicity, other imprinted genes not involved in IIS that negatively affect VSEL proliferation (H19 and p57Kip2) are not shown. 
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On the other hand (Figure 2), VSELs express functional 
IGF-1R and InsR and are susceptible to exogenous 
circulating paracrine IGF1 and insulin (Ins). Therefore, a 
chronic increase in caloric uptake that elevates circulating 
levels of IGF1 and Ins may contribute over time to 
depletion of these cells from adult tissues, affect the 
generation of VSEL-derived TCSCs, and thus negatively 
affect life span. This explains why mice that have high 
levels of circulating blood plasma IGF1 and enhanced IIS 
display accelerated depletion of VSELs and have a 




New data from our group and other groups has provided 
more evidence on the existence and biological role of 
primitive embryonic-like stem cells in murine adult 
tissues and their potential role in i) tissue organ 
rejuvenation, ii) longevity, and iii) regeneration/repair 
of damaged tissues.  
  
While murine BM-derived VSELs have been 
extensively characterized, we are aware that more work 
is needed to better characterize these small cells at the 
molecular level in humans. We need to determine 
whether human VSELs have the same molecular 
signature (e.g., an open chromatin structure at the Oct4 
promoter, modification of somatic imprinting, and the 
presence of bivalent domains) as their murine 
counterparts. If we can confirm that a similar 
mechanism operates for human and murine BM-derived 
UCB-VSELs, perhaps a controlled modulation of the 
somatic imprinted state to produce proper de novo 
methylation of somatic imprinted genes on the maternal 
and paternal chromosomes could increase the 
regenerative power of these cells.  
 
Finally, our work on murine VSELs has for the first 
time connected the role of caloric restriction/uptake, 
IIS, and the number of VSELs playing a potential role 
in tissue and organ rejuvenation [83,85]. An increase in 
chronic caloric uptake leads to an increase in IIS and 
may prematurely deplete VSELs from adult tissues, thus 
contributing to aging. By contrast, caloric restriction has 
an opposing beneficial effect on the tissue-residing pool 
of VSELs and longevity. Based on the encouraging 
studies on VSELs in the murine BM, further studies are 
needed to evaluate whether the number of VSELs in 
other adult murine tissues is also sensitive to IIS and 
correlates with life span. Similar studies have also to be 
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